133 related articles for article (PubMed ID: 6509453)
41. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
42. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
[TBL] [Abstract][Full Text] [Related]
43. Simple method for the administration of high-dose etoposide during autologous bone marrow transplantation.
Lazarus HM; Creger RJ; Diaz D
Cancer Treat Rep; 1986 Jun; 70(6):819-20. PubMed ID: 3524832
[No Abstract] [Full Text] [Related]
44. High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study.
Wolff SN; Johnson DH; Hainsworth JD; Greco FA
J Clin Oncol; 1984 Apr; 2(4):271-4. PubMed ID: 6368760
[TBL] [Abstract][Full Text] [Related]
45. Phase II trial of etoposide in advanced prostate cancer.
Trump DL; Loprinzi CL
Cancer Treat Rep; 1984 Sep; 68(9):1195-6. PubMed ID: 6478456
[No Abstract] [Full Text] [Related]
46. Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
Gockerman JP; Bartolucci AA; Nelson MO; Silberman H; Velez-Garcia E; Stein R
Cancer Treat Rep; 1986 Jun; 70(6):801-2. PubMed ID: 3524829
[No Abstract] [Full Text] [Related]
47. When is autologous bone marrow transplantation safe after high-dose treatment with etoposide?
Littlewood TJ; Spragg BP; Bentley DP
Clin Lab Haematol; 1985; 7(3):213-8. PubMed ID: 3907938
[TBL] [Abstract][Full Text] [Related]
48. Phase I and pharmacokinetic study of etoposide phosphate.
Brooks DJ; Srinivas NR; Alberts DS; Thomas T; Igwemzie LM; McKinney LM; Randolph J; Schacter L; Kaul S; Barbhaiya RH
Anticancer Drugs; 1995 Oct; 6(5):637-44. PubMed ID: 8845473
[TBL] [Abstract][Full Text] [Related]
49. A phase I trial of continuous infusion VP16-213 (etoposide).
Aisner J; Van Echo DA; Whitacre M; Wiernik PH
Cancer Chemother Pharmacol; 1982; 7(2-3):157-60. PubMed ID: 7083457
[TBL] [Abstract][Full Text] [Related]
50. Etoposide (VP-16-213).
Issell BF; Crooke ST
Cancer Treat Rev; 1979 Jun; 6(2):107-24. PubMed ID: 385138
[No Abstract] [Full Text] [Related]
51. [A phase II trial of etoposide (VP-16) administered intravenously in the treatment of malignant lymphoma and acute leukemia].
Moriyama Y; Shibata A; Maekawa I; Yoshida Y; Miura A; Wakui A; Kariyone S; Maekawa T; Miura Y; Abe T
Rinsho Ketsueki; 1985 Nov; 26(11):1774-84. PubMed ID: 3835288
[No Abstract] [Full Text] [Related]
52. Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma.
Ahmann DL; Bisel HF; Edmonson JH; Hahn RG; O'Connell MJ; Frytak S
Cancer Treat Rep; 1976 Nov; 60(11):1681-2. PubMed ID: 1021239
[No Abstract] [Full Text] [Related]
53. A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study.
Bennett JM; Lymann GH; Cassileth PA; Glick JH; Oken MM
Am J Clin Oncol; 1984 Oct; 7(5):471-3. PubMed ID: 6594926
[TBL] [Abstract][Full Text] [Related]
54. Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma.
Schell FC; Yap HY; Hortobagyi GN; Issell B; Esparza L
Cancer Chemother Pharmacol; 1982; 7(2-3):223-5. PubMed ID: 7083463
[No Abstract] [Full Text] [Related]
55. Etoposide as a single agent in relapsed advanced lymphomas. A phase II study.
Taylor RE; McElwain TJ; Barrett A; Peckham MJ
Cancer Chemother Pharmacol; 1982; 7(2-3):175-7. PubMed ID: 7083459
[TBL] [Abstract][Full Text] [Related]
56. Mitoxantrone: potential for use in intensive therapy.
LeMaistre CF; Herzig R
Semin Oncol; 1990 Feb; 17(1 Suppl 3):43-8. PubMed ID: 2406923
[TBL] [Abstract][Full Text] [Related]
57. [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].
Schmoll HJ; Niederle N; Achterrath W
Klin Wochenschr; 1981 Nov; 59(21):1177-88. PubMed ID: 7031350
[TBL] [Abstract][Full Text] [Related]
58. Pilot studies of various combinations of dibromodulcitol, VP-16, and AMSA.
Eagan RT
Oncology; 1982; 39(5):295-7. PubMed ID: 6896559
[TBL] [Abstract][Full Text] [Related]
59. Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC).
Chapman R; Itri L; Gralla R; Kelsen D; Casper E; Golbey R
Cancer Chemother Pharmacol; 1982; 7(2-3):205-7. PubMed ID: 7083460
[TBL] [Abstract][Full Text] [Related]
60. [New antineoplastic drugs of the podophyllotoxin derivative group].
Robak T; Płuzańska A
Pol Tyg Lek; 1983 Jan; 38(1):27-30. PubMed ID: 6346283
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
